a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): ...
[29]S Krause,et al.Abstract OT2-07-01:DETECT V/CHEVENDO–Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer....
[29]S Krause,et al.Abstract OT2-07-01:DETECT V/CHEVENDO–Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer....
L. et al. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res. 82 (Suppl. 4), Abstr. P2-13-07 (2022). Article Google Scholar Geuijen, C. A. et al. ...
[12]Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction...
Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99 TChemo) versus the upfront combination of T and chemo (TChemo) in patients with HER2+ advanced breast cancer.Materials and ...
HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence Background/aim: In estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, standard chemotherapies as well... H Yamashita,N Ishida,Y Hatanak...
LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann. Oncol. 32, S1331 (2021). Article Google Scholar Zhang, Z...
(3)新辅助治疗后接受R0手术。(4)术后接受辅助治疗。(5)临床病理资料完整。排除标准:(1)首诊Ⅳ期乳腺癌。(2)新辅助治疗疗程<4个周期。(3)未接受R0手术。(4)临床病理资料不完全。本研究已通过北京大学第一医院伦理委员会审批(No....
Neoadjuvant pyrotinib, trastuzumab,and docetaxel for HER2-positive breast can‐ cer(PHEDRA):a double-blind,randomized phase 3 trial [J]. BMC Med,2022,20(1):498. [26] COSTA R B,KURRA G,GREENBERG L,et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemo‐ therapy regimens ...